Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion

Zhang, Shuang; An, Ning; Ha, Wen-Jing; Zhang, Shaochi; Hu, Xiaowen; Ma, Aihua; Zhao, Bojun

doi:10.1177/0300060515617386

Cited by 6 publications

(6 citation statements)

References 40 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SCORE study ( n = 411) showed that the outcome of IVTA 1 mg groups is similar to IVTA 4 mg groups and can lower the rate of adverse events [131]. TA has numerous mechanisms of action, including anti-inflammatory effects, antiangiogenic properties and inhibition of VEGF, and other inflammatory cytokine expressions, such as IL-6, ICAM-1, and MCP-1 [132, 133]. Ozkiris et al evaluated the effect of TA injection on persistent CME in BRVO that failed to respond to previous laser photocoagulation.…”

Section: Treatmentmentioning

confidence: 99%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years.

show abstract

Section: Treatmentmentioning

confidence: 99%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…48 This therapeutic success seems to be associated with the anti-inflammatory and antiangiogenic properties of TA such as downregulation of VEGF, IL-6, ICAM-1, and MCP-1. 49,50 However, the use of TA-IVTs is linked to severe adverse events (AEs) some of them related to IVTs and others associated with the drug itself, such as increased intraocular pressure (IOP) and cataract progression. [51][52][53][54][55][56][57] In consequence, the use of anti-VEGF agents as primary therapy prevails over steroids in BRVO.…”

Section: Introductionmentioning

confidence: 99%

Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study

Navarro-Partida

Altamirano-Vallejo

López-Naranjo

et al. 2020

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To explore safety and therapeutic efficacy of a topical ophthalmic triamcinolone acetonide-loaded liposome formulation (TA-LF) as primary therapy in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods: Twelve eyes of 12 patients with ME secondary to BRVO were exposed to a topical instillation of 1 drop of TA-LF (TA 0.2%) 6 times a day for 12 weeks to evaluate safety and efficacy. Best corrected visual acuity (BCVA) intraocular pressure (IOP), slit lamp examination, and central foveal thickness (CFT) were analyzed at every visit. In addition, the morphology of TA-LF was analyzed using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Results: Patients presented a significant improvement of BCVA and CFT without significant IOP modification (P = 0.94). Treated eyes showed BCVA improvement from 40-12.05 to 64.83-15.97 letters and CFT reduction from 682.91-278.60 to 271.58-57.66 mm after 12 weeks of TA-LF therapy (P < 0.001). No adverse events, including IOP rising, were registered. SEM analysis of liposomal formulations showed that liposome (LP) size depends on its concentration. As the concentration of TA increased, the average size of LPs and the number of larger particles increased as well. TEM study displayed that LP formulation efficiently solubilizes TA crystals in nanoparticles and encapsulates them. Conclusion: LPs can function as nanocarriers of TA and they could be used as topical ophthalmic primary therapy instead of intravitreal drugs in patients with ME secondary to BRVO.

show abstract

“…In contrast to our study, Zhang et al detected other predictors of better response to intravitreal injection of TA including younger age, ME of recent onset, the presence of serous retinal detachment, BRVO of non ischemic type and coexistent systemic diseases. 31 …”

Section: Discussionmentioning

confidence: 99%

Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients

Nawar¹

2022

OPTH

View full text Add to dashboard Cite

Purpose The present study evaluated the efficacy of combined suprachoroidal injection of triamcinolone acetonide (TA) using a modified microneedle with intravitreal injection of ranibizumab in branch retinal vein occlusion (BRVO) patients. Patients and methods This is a prospective randomised interventional study that was conducted on 60 eyes of 60 patients with non ischemic BRVO. Patients were divided in two groups, group (1) 30 patients who received intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab, group (2) included 30 patients who received baseline combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL), both groups received monthly injection of ranibizumab on pro-re-nata (PRN) regimen for 1 year duration of the study. Results Group 2 received less number of injections (2.47 ± 1.2) as compared to group 1 (4.4 ± 1.5). Both groups achieved significant reduction of central macular thickness (CMT) after 12 months of injection with p value <0.001. Both groups showed significant improvement of best corrected visual acuity (BCVA) after 12 months with p value <0.001. Group 2 showed more significant improvement of BCVA after 6 and 12 months. The baseline CMT and the number of injections were the main predictors of the final BCVA in group 1, while the baseline BCVA was the only predictor of final BCVA in group 2. Conclusion Combined suprachoroidal injection of TA using this modified microneedle with intravitreal injection of ranibizumab resulted in more significant improvement of BCVA and reduction of CMT compared with ranibizumab monotherapy with no reported ocular or systemic side effects. The study was prospectively registered with clinical trial.gov ID (NCT04690608) in 27-12-2020.

show abstract

Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion

Cited by 6 publications

References 40 publications

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study

Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients

Contact Info

Product

Resources

About